Afshin Dowlati
- Oncology top 0.1%
- Pulmonary and Respiratory Medicine top 0.1%
- Molecular Biology top 1%
- Cancer Research top 0.5%
- Epidemiology top 1%
- Co-authors
- Joan H. SchillerJulie R. BrahmerRobert J. GrayMichael C. PerryRogério LilenbaumDavid H. JohnsonAlan SandlerScot C. Remick
- Topics
- Lung Cancer Research Studies (134 papers)Lung Cancer Treatments and Mutations (112 papers)Cancer therapeutics and mechanisms (64 papers)
- Partner nations
- United StatesSpainUnited Kingdom
In The Last Decade
Afshin Dowlati
378 papers receiving 15.9k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 9.5k
- Pulmonary and Respiratory Medicine 6.7k
- Molecular Biology 6.0k
- Cancer Research 2.4k
- Epidemiology 2.0k
Countries citing papers authored by Afshin Dowlati
This map shows the geographic impact of Afshin Dowlati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Afshin Dowlati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Afshin Dowlati more than expected).
Fields of papers citing papers by Afshin Dowlati
This network shows the impact of papers produced by Afshin Dowlati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Afshin Dowlati. The network helps show where Afshin Dowlati may publish in the future.
Co-authorship network of co-authors of Afshin Dowlati
This figure shows the co-authorship network connecting the top 25 collaborators of Afshin Dowlati. A scholar is included among the top collaborators of Afshin Dowlati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Afshin Dowlati. Afshin Dowlati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03breakdown → | 18 |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| 6 | 8 | |
| 7 | 5 | |
| 8 | 18 | |
| 9 | 6 | |
| 10 | 10 | |
| 11 | 229 | |
| 12 | 37 | |
| 13 | 16 | |
| 14 | 55 | |
| 15 | 0 | |
| 16 | 81 | |
| 17 | 149 | |
| 18 | 208 | |
| 19 | 57 | |
| 20 | Comparison of positron emission tomography and computed tomography in the mediastinal and extrathoracic staging of non-small cell lung cancer | 2 |
About Afshin Dowlati
Afshin Dowlati is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 395 papers that have together received 16.2k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (134 papers), Lung Cancer Treatments and Mutations (112 papers) and Cancer therapeutics and mechanisms (64 papers). The work is most often cited by research in Oncology (9.5k citations), Pulmonary and Respiratory Medicine (6.7k citations) and Internal Medicine (672 citations). Afshin Dowlati has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Joan H. Schiller, Julie R. Brahmer, Robert J. Gray, Michael C. Perry, Rogério Lilenbaum, David H. Johnson, Alan Sandler, Scot C. Remick, Pingfu Fu and Nathan Levitan. Their work appears in journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.